Primary Job Title President Primary Organization 
PinkNotes
Location Greensboro, North Carolina, United States Regions East Coast, Southern US Gender Male
LinkedIn View on LinkedIn
Mark Goldberg was appointed a member of the Company’s Board in January 2014. He has served as Senior Vice President for Medical and Regulatory Affairs at Synageva BioPharma since September, 2011, and previously was a member of the Board of Directors for private Synageva from 2008 to September 2011.
Before joining the management team at Synageva
he served in various management capacities of increasing responsibility at Genzyme Corporation from 1996 to 2011, most recently as Senior Vice President for Clinical Development and Global Therapeutic Group Head for Oncology and Personalized Genetic Health.
He was also the Chairman of Genzyme’s Early Product Review Board. While at Genzyme, he played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme®, Aldurazyme®, Myozyme® and Lumizyme®.
Prior to joining Genzyme, he was a full-time staff physician at Brigham and Women’s Hospital and the Dana-Farber Institute, where he still holds appointments. Dr. Goldberg is a Clinical Associate Professor of Medicine at Harvard Medical School.
Additionally, he has been a member of the Board of Directors of Immunogen where he has served on the governance and nominating committee since November, 2011, and he has been a member of the Board of Directors of the New England Division of the American Cancer Society since 2010.
Dr. Goldberg received his A.B from Harvard College and holds a Doctor of Medicine degree from Harvard Medical School.
He was on the Brigham and Women’s Hospital medical housestaff from 1981–84 and completed his hematology/oncology fellowship at Brigham and Women’s Hospital and the Dana Farber Cancer Institute.
Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers.
